@PCHARBONNEL01 Ce n'est pas totalement la conclusion de la revue Cochrane de 2021 sur l'arrêt de ces traitements chez les personnes avec des troubles neurocognitifs maeurs liés à une maladie d'Alzheimer : https://t.co/rue0Wj3c3q Ni la conclusion d'une étu
#IAChE #Alzheimer Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia 1/2 https://t.co/yssqPKXmXD
Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia https://t.co/d7laAmuNoG
MA: discontinuing cholinesterase inhibitors may result in worse cognitive function up to 2 or 11 months (SMD= ‐0.42; ‐0.64 to ‐0.21; ‐0.62; ‐0.94 to ‐0.31, respectively) and neuropsychiatric symptoms vs. continuing treatment, in patients with Alzheimer htt
@MeMeDocMa La qualité de vie est d'abord impactée par le retentissement fonctionnel / les troubles psychocomportementaux. On peut voir 2 Cochrane en 2021 sur IACh / démence : Alzheimer : https://t.co/A8Xbkb7AGj Démence vasculaire : https://t.co/0E5CXKKb
RT @WileyHealth: Listen to this new @CochraneLibrary #podcast on stopping or continuing anti-dementia drugs in patients with #dementia, wit…
Listen to this new @CochraneLibrary #podcast on stopping or continuing anti-dementia drugs in patients with #dementia, with the @CochraneDCIG lead author. Check it out here: https://t.co/eZep53G8O2 @CochraneIreland https://t.co/8CkzsRHcNN
Listen to this new @CochraneLibrary #podcast on stopping or continuing anti-dementia drugs in patients with #dementia, with the @CochraneDCIG lead author. Check it out here: https://t.co/yIoYJcT6QH @CochraneIreland https://t.co/kyLkhnEMbT
Listen to this new @CochraneLibrary #podcast on stopping or continuing anti-dementia drugs in patients with #dementia with the @CochraneDCIG lead author @CochraneIreland https://t.co/7H7QygLfRh https://t.co/GrDYMBmRyO
(CDSR) #Alzheimer Interrumpir inhibidores de la colinesterasa podría empeorar estado cognitivo, neuropsiquiátrico y funcional. Aunque estos fármacos se apoyan en evidencia limitada y certeza baja, falta evidencia para guiar decisiones sobre su interrupción
RT @ce_potter: Stop anti-dementia medications? New @CochraneDCIG review @DrCaroleParsons & coauthors @QUB_ARF support ongoing #RCT. 7 trail…
RT @DrCaroleParsons: Delighted to have our Cochrane Review published. Most evidence points to the benefits of continuing treatment with ChE…
RT @ce_potter: Stop anti-dementia medications? New @CochraneDCIG review @DrCaroleParsons & coauthors @QUB_ARF support ongoing #RCT. 7 trail…
Stop anti-dementia medications? New @CochraneDCIG review @DrCaroleParsons & coauthors @QUB_ARF support ongoing #RCT. 7 trails (0 memantine alone)n=759, saw 🛑ChEIs may be associated w/ worse short term outcomes but caution due to methodological uncertai
RT @QUB_ARF: Excellent work from @DrCaroleParsons and our very own Dr. Bernadette McGuinness (@Bernade84181190) and Professor Peter Passmor…
RT @DrCaroleParsons: Delighted to have our Cochrane Review published. Most evidence points to the benefits of continuing treatment with ChE…
RT @QUB_ARF: Excellent work from @DrCaroleParsons and our very own Dr. Bernadette McGuinness (@Bernade84181190) and Professor Peter Passmor…
RT @QUB_ARF: Excellent work from @DrCaroleParsons and our very own Dr. Bernadette McGuinness (@Bernade84181190) and Professor Peter Passmor…
Excellent work from @DrCaroleParsons and our very own Dr. Bernadette McGuinness (@Bernade84181190) and Professor Peter Passmore (@OFMPP) on getting this Cochrane Review published. Click on the link below to read the full @CochraneDCIG review: https://t.co/
RT @DrCaroleParsons: Delighted to have our Cochrane Review published. Most evidence points to the benefits of continuing treatment with ChE…
RT @DrCaroleParsons: Delighted to have our Cochrane Review published. Most evidence points to the benefits of continuing treatment with ChE…
RT @DrCaroleParsons: Delighted to have our Cochrane Review published. Most evidence points to the benefits of continuing treatment with ChE…
Delighted to have our Cochrane Review published. Most evidence points to the benefits of continuing treatment with ChEIs, though this is supported by limited evidence in Alzheimer’s Disease only. No trials investigated stopping just memantine.
認知症患者における抗認知症薬の中止・継続について https://t.co/hiT4uMprm7
Is stopping cholinesterase inhibitors or memantine beneficial or harmful to people with dementia? Find out from this Cochrane Review #CochraneEvidence https://t.co/EdeUqlvdsv
RT @CochraneLibrary: Stopping or continuing anti‐dementia drugs in patients with #dementia - https://t.co/HrcMr66aan New @CochraneDCIG syst…
Stopping or continuing anti‐dementia drugs in patients with #dementia - https://t.co/HrcMr66aan New @CochraneDCIG systematic review: "although there was uncertainty about the results, most of the evidence pointed to benefits of continuing treatment with ch
Retirada o continuación de inhibidores de la colinesterasa (IC) o memantina (M), en personas con demencia: la interrupción de IC puede obtener un peor estado cognitivo y funcional que el tratamiento continuo, con pruebas de certeza baja o muy baja. ... htt